Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Peter Clark, MA, MD, FRCP: A Payer Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Jun

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Peter Clark, MA, MD, FRCP: A Payer Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

New Research Links Low Alcohol Consumption to Elevated Health Risks

Digital Tool May Improve Patient Engagement in Oncology Clinical Trials

GLP-1 RAs May Reduce Risk of Obesity-Related Cancers

Teclistamab in Previously Treated Multiple Myeloma

Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer